TCIM

Summary

TCIM (transcriptional and immune response regulator, HGNC:1357) is a protein-coding gene on chromosome 8p11.21, encoding Transcriptional and immune response regulator (Q9NR00). Seems to be involved in the regulation of cell growth an differentiation, may play different and opposite roles depending on the tissue or cell type.

This gene encodes a small, monomeric, predominantly unstructured protein that functions as a positive regulator of the Wnt/beta-catenin signaling pathway. This protein interacts with a repressor of beta-catenin mediated transcription at nuclear speckles. It is thought to competitively block interactions of the repressor with beta-catenin, resulting in up-regulation of beta-catenin target genes. The encoded protein may also play a role in the NF-kappaB and ERK1/2 signaling pathways. Expression of this gene may play a role in the proliferation of several types of cancer including thyroid cancer, breast cancer and hematological malignancies.

Source: NCBI Gene 56892 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 1 total
• MANE Select transcript: NM_020130

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1357
Approved symbol	TCIM
Name	transcriptional and immune response regulator
Location	8p11.21
Locus type	gene with protein product
Status	Approved
Aliases	TC-1, hTC-1, TC1
Ensembl gene	ENSG00000176907
Ensembl biotype	protein_coding
OMIM	607702
Entrez	56892

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000315792

RefSeq mRNA: 1 — MANE Select: NM_020130 NM_020130

CCDS: CCDS6115

Canonical transcript exons

ENST00000315792 — 1 exons

Exon	Start	End
ENSE00001254573	40153482	40155310

Expression profiles

Bgee: expression breadth ubiquitous, 259 present calls, max score 99.26.

FANTOM5 (CAGE): breadth broad, TPM avg 13.7123 / max 1161.8933, expressed in 816 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
88626	13.6688	815
88624	0.0288	11
88625	0.0147	2

Top tissues by expression

283 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
parotid gland	UBERON:0001831	99.26	gold quality
gall bladder	UBERON:0002110	98.37	gold quality
right lung	UBERON:0002167	98.19	gold quality
vena cava	UBERON:0004087	97.69	gold quality
mucosa of urinary bladder	UBERON:0001259	97.64	gold quality
seminal vesicle	UBERON:0000998	97.57	gold quality
upper lobe of left lung	UBERON:0008952	97.35	gold quality
metanephros cortex	UBERON:0010533	97.35	gold quality
pericardium	UBERON:0002407	97.32	gold quality
upper lobe of lung	UBERON:0008948	97.24	gold quality
lung	UBERON:0002048	96.94	gold quality
visceral pleura	UBERON:0002401	96.70	gold quality
rectum	UBERON:0001052	96.53	gold quality
lower lobe of lung	UBERON:0008949	96.40	gold quality
right lobe of liver	UBERON:0001114	96.35	gold quality
ventricular zone	UBERON:0003053	96.21	gold quality
endometrium	UBERON:0001295	95.17	gold quality
muscle layer of sigmoid colon	UBERON:0035805	95.04	gold quality
colonic epithelium	UBERON:0000397	94.96	gold quality
mucosa of sigmoid colon	UBERON:0004993	94.60	gold quality
right atrium auricular region	UBERON:0006631	94.50	gold quality
mucosa of paranasal sinus	UBERON:0005030	94.49	gold quality
saliva-secreting gland	UBERON:0001044	94.32	gold quality
heart right ventricle	UBERON:0002080	94.11	gold quality
urinary bladder	UBERON:0001255	93.89	gold quality
vermiform appendix	UBERON:0001154	93.69	gold quality
adult organism	UBERON:0007023	93.64	gold quality
cardiac atrium	UBERON:0002081	93.62	gold quality
liver	UBERON:0002107	93.61	gold quality
smooth muscle tissue	UBERON:0001135	93.56	gold quality

Single-cell (SCXA)

Detected in 16 experiment(s), a significant marker in 14.

Experiment	Marker?	Max mean expression
E-GEOD-84465	yes	991.38
E-HCAD-1	yes	89.82
E-MTAB-10553	yes	49.14
E-MTAB-6701	yes	44.00
E-HCAD-10	yes	43.75
E-MTAB-10287	yes	39.06
E-GEOD-135922	yes	38.77
E-MTAB-8410	yes	25.36
E-GEOD-130148	yes	19.91
E-CURD-46	yes	15.61
E-GEOD-83139	yes	11.50
E-GEOD-125970	yes	7.74
E-GEOD-137537	yes	6.13
E-HCAD-11	no	3062.64
E-MTAB-10137	no	6.57

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

97 targeting TCIM, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-454-3P	99.91	74.01	1925
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-130A-3P	99.90	73.31	1861
HSA-MIR-130B-3P	99.90	73.27	1850
HSA-MIR-301A-3P	99.90	73.15	1839

Literature-anchored findings (GeneRIF, showing 20)

• Overexpression of TC-1 may be important in thyroid carcinogenesis. (PMID:15087392)
• data indicate that TC1 is a novel upstream regulator of the Wnt/beta-catenin pathway that enhances aggressive behavior of cancers (PMID:16424001)
• The TC1 coordinates the up-regulation of Wnt/beta-catenin target genes that are implicated in the aggressive biological behavior of cancers. (PMID:16740781)
• Gene induces transformed phenotype when overexpressed in a cancer breast cell line. (PMID:17178857)
• TC-1 over expression is transforming and may link with the FGFR pathway in a subset of breast cancer. (PMID:17520678)
• Our data suggest that TC1 is a novel heat shock response regulator. (PMID:17603013)
• intrinsically disordered TC-1 interacts with Cby via its transient helical structure (PMID:17905836)
• TC1 was involved in the mitogen-activated ERK1/2 signaling pathway and positively regulated G(1)- to S-phase transition of the cell cycle. (PMID:18959821)
• A significant association was found between the copy-number deletions of C8orf4 and the risk of hematological malignancies. (PMID:20878554)
• The SNP rs10958605 in the C8orf4 gene had the smallest p value in analyses of the motor outcome. (PMID:22658654)
• The higher expression of TC-1 in ovarian compared to colorectal adenocarcinomas suggests its potential use as a marker (PMID:23377761)
• TC-1 expression is associated with aggressive biologic behavior in lung cancer and might coordinate with the Wnt/beta-catenin pathway as a positive upstream regulator that induces these behaviors. (PMID:23880650)
• TC-1 overexpression promotes cell proliferation in human non-small cell lung cancer that can be inhibited by PD173074. (PMID:24941347)
• the high expression of TC1 was common in oral tongue squamous cell carcinomas and correlated with the expression of b-catenin and cyclin D1 and the progression of oral tongue squamous cell carcinomas (PMID:25869879)
• C8orf4 negatively regulates the self-renewal of liver CSCs via suppression of NOTCH2 signalling (PMID:25985737)
• Decreased capacity of fibrotic lung fibroblasts to up-regulate COX-2 expression and COX-2-derived PGE2 synthesis is due to an indirect epigenetic mechanism involving hypermethylation of the transcriptional regulator, c8orf4. (PMID:26744410)
• Identified a new circRNA, circZFR, that was significantly upregulated in papillary thyroid carcinoma (PTC). CircZFR could promote C8orf4 expression via serving as a competing endogenous RNA of miR-1261 in PTC cells. Rescue assays indicated that restoration of C8orf4 significantly attenuated the inhibitory effects of circZFR knockdown on PTC cell proliferation, migration and invasion. (PMID:29842886)
• The lncRNA H19 serves as a competing endogenous RNA (ceRNA) for miR-30a to augment miR-30a downstream target C8orf4, therefore modulating adipogenic differentiation in adipose tissue-derived mesenchymal stem cells. (PMID:31026067)
• Correlations of ultrasound and pathological features of thyroid carcinoma with TC-1 mRNA and protein expression. (PMID:31081098)
• The expressions of C8orf4 (TCIM) and beta-catenin increase synergystically in cervical squamous cell carcinoma (CSCC) and high-grade intraepithelial lesions compared with low-grade lesions and normal cervical tissues. The methylation level of C8orf4 is decreased in CSCCs and is responsible for the increased expression of C8orf4. (PMID:31374065)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	tcimb	ENSDARG00000076858
danio_rerio	tcima	ENSDARG00000079497
mus_musculus	Tcim	ENSMUSG00000056313
rattus_norvegicus	Tcim	ENSRNOG00000047977

Protein

Protein identifiers

Transcriptional and immune response regulator — Q9NR00 (reviewed: Q9NR00)

Alternative names: Thyroid cancer protein 1

All UniProt accessions (1): Q9NR00

UniProt curated annotations — full annotation on UniProt →

Function. Seems to be involved in the regulation of cell growth an differentiation, may play different and opposite roles depending on the tissue or cell type. May enhance the WNT-CTNNB1 pathway by relieving antagonistic activity of CBY1. Enhances the proliferation of follicular dendritic cells. Plays a role in the mitogen-activated MAPK2/3 signaling pathway, positively regulates G1-to-S-phase transition of the cell cycle. In endothelial cells, enhances key inflammatory mediators and inflammatory response through the modulation of NF-kappaB transcriptional regulatory activity. Involved in the regulation of heat shock response, seems to play a positive feedback with HSF1 to modulate heat-shock downstream gene expression. Plays a role in the regulation of hematopoiesis even if the mechanisms are unknown. In cancers such as thyroid or lung cancer, it has been described as promoter of cell proliferation, G1-to-S-phase transition and inhibitor of apoptosis. However, it negatively regulates self-renewal of liver cancer cells via suppresion of NOTCH2 signaling.

Subunit / interactions. Monomer. Interacts with NOTCH2 (via ANK repeats), the interaction inhibits the nuclear translocation of NOTCH2 N2ICD. Interacts (C-terminus) with CBY1 (C-terminus), TCIM competes with CTNNB1 for the interaction with CBY1.

Subcellular location. Cytoplasm. Nucleus. Nucleolus. Nucleus speckle.

Tissue specificity. Ubiquitous. Expressed in thyroid papillary carcinoma. Expressed in liver, expression levels decrease in hepatocellular carcinoma. Slightly detected in normal lung, its expression is highly induced in lung cancer cells (at protein level).

Induction. Induced by pro-inflammatory cytokines such as TNF and IL1B, via NF-kappaB signaling. Induced by cellular stresses such as heat shock, TPA, lipopolysaccharide and UV. Induced by mitogens such as thrombin.

RefSeq proteins (1): NP_064515* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR020282	Avpi1/C8orf4_dom	Domain
IPR039580	Tcim	Family

Pfam: PF15063

UniProt features (6 total): mutagenesis site 4, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NR00-F1	79.01	0.30

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (4):

Position	Phenotype
74	no effect on interaction with cby1.
86	abolishes interaction with cby1. forms irregular perinuclear cytoplasmic aggregates.
88	abolishes interaction with cby1.
96	no effect on interaction with cby1. accumulates at nucleoli periphery.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 181 (showing top): GSE45365_NK_CELL_VS_BCELL_UP, WALLACE_PROSTATE_CANCER_RACE_UP, FISCHER_G1_S_CELL_CYCLE, SHEPARD_CRASH_AND_BURN_MUTANT_UP, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GOBP_CELL_CYCLE_PHASE_TRANSITION, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GOBP_NEGATIVE_REGULATION_OF_NOTCH_SIGNALING_PATHWAY, GOBP_CELL_ACTIVATION_INVOLVED_IN_IMMUNE_RESPONSE, MARTINEZ_RB1_TARGETS_UP, PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_UP, GOBP_REGULATION_OF_HEMOPOIESIS, AMIT_EGF_RESPONSE_120_HELA, GOBP_POSITIVE_REGULATION_OF_NON_CANONICAL_NF_KAPPAB_SIGNAL_TRANSDUCTION, ACEVEDO_LIVER_TUMOR_VS_NORMAL_ADJACENT_TISSUE_DN

GO Biological Process (11): endothelial cell activation involved in immune response (GO:0002264), regulation of DNA-templated transcription (GO:0006355), apoptotic process (GO:0006915), cellular response to heat (GO:0034605), negative regulation of Notch signaling pathway (GO:0045746), positive regulation of non-canonical NF-kappaB signal transduction (GO:1901224), regulation of cell cycle G1/S phase transition (GO:1902806), regulation of hemopoiesis (GO:1903706), obsolete positive regulation of protein kinase A signaling (GO:0010739), negative regulation of apoptotic process (GO:0043066), positive regulation of protein kinase C activity (GO:1900020)

GO Molecular Function (2): Notch binding (GO:0005112), protein binding (GO:0005515)

GO Cellular Component (7): nucleus (GO:0005634), nucleoplasm (GO:0005654), nucleolus (GO:0005730), cytoplasm (GO:0005737), cytosol (GO:0005829), plasma membrane (GO:0005886), nuclear speck (GO:0016607)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
nuclear lumen	2
cell activation involved in immune response	1
immune response	1
endothelial cell activation	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
response to heat	1
cellular response to stress	1
Notch signaling pathway	1
regulation of Notch signaling pathway	1
negative regulation of signal transduction	1
non-canonical NF-kappaB signal transduction	1
regulation of non-canonical NF-kappaB signal transduction	1
positive regulation of intracellular signal transduction	1
cell cycle G1/S phase transition	1
regulation of cell cycle phase transition	1
regulation of immune system process	1
hemopoiesis	1
regulation of cell development	1
regulation of multicellular organismal development	1
apoptotic process	1
regulation of apoptotic process	1
negative regulation of programmed cell death	1
diacylglycerol-dependent serine/threonine kinase activity	1
positive regulation of protein serine/threonine kinase activity	1
regulation of protein kinase C activity	1
signaling receptor binding	1
binding	1
intracellular membrane-bounded organelle	1
intracellular membraneless organelle	1
intracellular anatomical structure	1
cytoplasm	1
membrane	1
cell periphery	1
nuclear ribonucleoprotein granule	1

Protein interactions and networks

STRING

344 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TCIM	BAG4	O95429	880
TCIM	LSM1	O15116	798
TCIM	CBY1	Q9Y3M2	669
TCIM	NOTCH2	Q04721	565
TCIM	BAG2	O95816	496
TCIM	LSM6	P62312	478
TCIM	LSM8	O95777	474
TCIM	LSM3	P62310	470
TCIM	LSM7	Q9UK45	465
TCIM	LSM2	Q9Y333	463
TCIM	LSM4	Q9Y4Z0	453
TCIM	NQO2	P16083	428
TCIM	ARHGEF5	Q12774	425
TCIM	LSM5	Q9Y4Y9	423
TCIM	GNAO1	P09471	407

IntAct

22 interactions, top by confidence:

A	B	Type	Score
FBXW7	TCIM	psi-mi:“MI:2364”(proximity)	0.470
TCIM	FBXW7	psi-mi:“MI:0915”(physical association)	0.470
TCIM	ACO2	psi-mi:“MI:0915”(physical association)	0.400
BRAF	TCIM	psi-mi:“MI:2364”(proximity)	0.270
TCIM	SMARCA4	psi-mi:“MI:2364”(proximity)	0.270
SMARCA4	TCIM	psi-mi:“MI:2364”(proximity)	0.270
SPOP	TCIM	psi-mi:“MI:2364”(proximity)	0.270
TCIM	SPOP	psi-mi:“MI:2364”(proximity)	0.270
TCIM	PTEN	psi-mi:“MI:2364”(proximity)	0.270
TCIM	PTPN11	psi-mi:“MI:2364”(proximity)	0.270
TCIM	TP53	psi-mi:“MI:2364”(proximity)	0.270
TCIM	EGFR	psi-mi:“MI:2364”(proximity)	0.270
AKT1	TCIM	psi-mi:“MI:2364”(proximity)	0.270
livM2	TCIM	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (4): C8orf4 (Proximity Label-MS), C8orf4 (Affinity Capture-RNA), C8orf4 (Affinity Capture-MS), C8orf4 (Affinity Capture-RNA)

ESM2 similar proteins: A0A1B0GVR7, A0PJW8, A2BYT2, A5FRX9, B8G1X0, C1DKL7, G3UWD5, O42659, O62953, O95567, O98453, P05899, P11690, P11794, P19718, P20920, P27975, P32544, P33482, P39971, P52776, P54446, P69516, P69517, P86209, Q02781, Q0ABH1, Q1X6Y0, Q3AMN4, Q3J8R8, Q3K5Z2, Q3MFB7, Q3ZZM0, Q537H7, Q57P89, Q5I162, Q5PHY6, Q6AY31, Q75003, Q7CQJ0

Diamond homologs: Q3SZR0, Q5E969, Q9D7H4, Q9D915, Q9NR00, Q5R8D4, Q5T686, Q8VDA6

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

1 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

87 predictions. Top by Δscore:

Variant	Effect	Δscore
8:40153873:G:GT	donor_gain	0.7600
8:40153906:G:GG	donor_gain	0.7600
8:40154442:A:AG	acceptor_gain	0.7500
8:40153903:CAAGT:C	donor_loss	0.5900
8:40153904:AAGT:A	donor_loss	0.5900
8:40153905:AG:A	donor_loss	0.5900
8:40153907:T:A	donor_loss	0.5900
8:40153908:GAGT:G	donor_loss	0.5800
8:40153909:A:AC	donor_loss	0.5700
8:40153910:G:C	donor_loss	0.5700
8:40153902:CCAA:C	donor_gain	0.5400
8:40153910:GTTT:G	donor_gain	0.5200
8:40153918:G:GT	donor_gain	0.5200
8:40153901:ACCAA:A	donor_gain	0.5000
8:40153909:A:AG	donor_gain	0.5000
8:40153904:AA:A	donor_gain	0.4800
8:40153903:CAA:C	donor_gain	0.4700
8:40154071:GA:G	acceptor_gain	0.4500
8:40153908:GA:G	donor_gain	0.4400
8:40154071:GAGGA:G	acceptor_gain	0.4400
8:40154070:A:AG	acceptor_gain	0.4100
8:40154071:G:GG	acceptor_gain	0.4100
8:40153867:GA:G	donor_gain	0.3800
8:40153868:A:G	donor_gain	0.3700
8:40153969:CAGGA:C	acceptor_gain	0.3700
8:40154046:C:CT	acceptor_gain	0.3300
8:40154062:G:T	acceptor_gain	0.3300
8:40154125:A:T	donor_gain	0.3300
8:40154129:G:GT	donor_gain	0.3300
8:40154040:TCCA:T	acceptor_gain	0.3200

AlphaMissense

699 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:40153687:T:C	F52S	0.998
8:40153626:C:A	R32S	0.997
8:40153721:A:C	R63S	0.997
8:40153721:A:T	R63S	0.997
8:40153631:G:C	K33N	0.994
8:40153631:G:T	K33N	0.994
8:40153684:T:C	L51P	0.994
8:40153702:A:C	D57A	0.994
8:40153702:A:T	D57V	0.994
8:40153774:T:C	L81P	0.994
8:40153651:T:C	F40S	0.993
8:40153686:T:C	F52L	0.993
8:40153688:C:A	F52L	0.993
8:40153688:C:G	F52L	0.993
8:40153699:G:T	G56V	0.993
8:40153701:G:C	D57H	0.993
8:40153650:T:C	F40L	0.992
8:40153652:T:A	F40L	0.992
8:40153652:T:G	F40L	0.992
8:40153687:T:G	F52C	0.992
8:40153720:G:C	R63T	0.992
8:40153686:T:G	F52V	0.991
8:40153702:A:G	D57G	0.991
8:40153723:C:A	A64D	0.991
8:40153779:G:C	A83P	0.991
8:40153722:G:C	A64P	0.990
8:40153770:G:C	A80P	0.989
8:40153651:T:G	F40C	0.988
8:40153675:T:C	L48P	0.988
8:40153686:T:A	F52I	0.988

dbSNP variants (sampled 300 via entrez): RS1000097855 (8:40155633 G>T), RS1000400009 (8:40152942 G>A), RS1000771184 (8:40152743 T>C), RS1001369872 (8:40152536 C>G), RS1001655472 (8:40152109 C>G,T), RS1003437530 (8:40155485 AAG>A), RS1005683578 (8:40153254 T>C), RS1006586304 (8:40152806 T>G), RS1007995820 (8:40153957 C>G), RS1008174415 (8:40151664 C>G), RS1008552678 (8:40154378 G>A,C), RS1009125484 (8:40152985 C>A), RS1010250688 (8:40152696 G>A), RS1011263487 (8:40155685 G>C), RS1011516353 (8:40155185 G>C)

Disease associations

OMIM: gene MIM:607702 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST001546_1	Parkinson’s disease (motor and cognition)	2.000000e-06
GCST004748_133	Lung cancer	7.000000e-06
GCST012310_8	Schizophrenia x sex interaction	2.000000e-06
GCST012311_27	Schizophrenia x sex interaction	5.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0008343	sex interaction measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

67 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, increases expression	6
Tetrachlorodibenzodioxin	decreases expression, affects cotreatment, increases expression	4
trichostatin A	affects cotreatment, decreases expression	3
Cyclosporine	decreases expression, increases expression	3
bisphenol A	affects expression, increases expression	2
Temozolomide	increases response to substance, increases expression	2
Acetaminophen	decreases expression	2
Benzo(a)pyrene	affects methylation, increases expression	2
Cadmium	decreases expression, increases expression	2
Estradiol	affects cotreatment, increases expression, decreases expression, decreases reaction	2
Lipopolysaccharides	increases expression, affects expression, affects response to substance, decreases reaction	2
Nickel	increases expression	2
Oxygen	increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Aflatoxin B1	affects expression, decreases methylation	2
methylmercuric chloride	decreases expression, increases expression	1
arsenite	increases expression	1
sulforaphane	decreases expression	1
sodium arsenite	increases expression	1
nickel chloride	increases expression	1
zinc chromate	increases abundance, increases expression	1
manganese chloride	increases expression	1
S-(1,2-dichlorovinyl)cysteine	decreases reaction, increases expression	1
chromium hexavalent ion	increases expression, increases abundance	1
perfluorooctane sulfonic acid	decreases expression	1
entinostat	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression, decreases expression	1
abrine	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	increases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	increases expression, affects cotreatment	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.